AzTrials
AzTrials

Fibromyalgia (FM)NCT07323199

Exercise and Neuromodulation in Fibromyalgia

A study testing EXERCISE TRAINING WITH OR WITHOUT MEDICATION and Neuromodulators in people with Fibromyalgia (FM), run by Universidad Nacional Andres Bello at 1 site in Chile.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Exercise is recommended for people with fibromyalgia because it can reduce symptoms and improve quality of life. Some studies show that high-intensity exercises like running or cycling (also called high-intensity interval training, or HIIT) may reduce symptoms more effectively than slower, traditional exercises. Read more about this study

Who is it for?
Ages 18 to 65 years, women only
Conditions the study is for
Fibromyalgia (FM)
What is being tested?
EXERCISE TRAINING WITH OR WITHOUT MEDICATION and Neuromodulators
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteChile
Study dates
1 Jan 2026to Jun 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Women with a diagnosis of Fibromyalgia by a physician according to the criteria of the American College of Rheumatology (ACR) 2016
  • A stable medical treatment for symptoms for at least 4 weeks before participation (stable doses of medication)
  • Reported pain equal to or higher than 40 mm on the visual analogue scale (moderate or severe pain) for more than 3 months
  • Body mass index (BMI) between 18.5 and 39.9 kg m-2,
  • Controlled high blood pressure.

Who cannot join

  • Isolated inflammatory joint, cancer, infectious, traumatic, localised neuropathic or degenerative joint pain.
  • Intense headache, cerebral surgery, seizure/epilepsy, cardiovascular, lung, metabolic (II diabetes mellitus), retinopathy or neurological diseases (i.e. stroke and traumatic brain injury antecedents),
  • Severe psychiatric disorders, major depression
  • Substance abuse.
  • Currently pregnant/breastfeeding,
  • Under physical therapy treatment or have participated in a designed sports or exercise training in systematic programs in the last 3 months.
  • Unable to speak or read Spanish fluently (inability to understand the pain scale and cooperate in testing)

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Edith Elgueta Cancino, PhD contact

+56 22 6618606

edith.elgueta@unab.cl

Oscar Nuñez Dias, Msc contact

+56 22 6618028

o.nuezdiaz@uandresbello.edu

Chile1 site
  • Excercise and Rehabilitation Sciences Institute, Universidad Nacional Andres Bello

    Santiago, Santiago Metropolitan, 7591538

    Edith Elgueta Cancino, PhD, +56 22 6618606, edith.elgueta@unab.cl

Other trials in Chile

About this study

Official title: High-Intensity Interval Training (HIIT) and Transcranial Direct Current Stimulation (tDCS) in Women With Fibromyalgia - Effects on Clinical and Neuro-physiological Variables: Randomized Clinical Trial Protocol

Exercise is recommended for people with fibromyalgia because it can reduce symptoms and improve quality of life. Some studies show that high-intensity exercises like running or cycling (also called high-intensity interval training, or HIIT) may reduce symptoms more effectively than slower, traditional exercises.

There are also new treatments, like non-invasive neuromodulation, which uses a gentle current to stimulate brain cells. This technique can help reduce pain in people with fibromyalgia. However, we don't yet know if combining HIIT and neuromodulation works better than exercise alone. We also want to find out if this combination helps improve other symptoms like fatigue and poor sleep.

Read more

The goal of this study is to see how a combination of HIIT and neuromodulation affects pain, fatigue, sleep, and muscle strength in women with fibromyalgia.

The investigators are asking two main questions:

Does combining HIIT and neuromodulation reduce pain better than exercise alone? Does this combination improve how the brain controls pain, muscles, and other symptoms like fatigue and sleep problems? What Will the Study Involve?

Three different exercise training programs will be compared:

HIIT with neuromodulation (tDCS): The participant will do HIIT by cycling at a high intensity for 1 minute, then resting for 2 minutes. Then, this will be repeated 10 times. At the same time, the researchers will place two small, damp sponges on the head of the participant. These sponges connect to the tDCS device, which sends a gentle current to your brain. It might feel a tingling sensation at first, but it will fade away.

HIIT with a "sham" (inactive) neuromodulation: This is similar to the first program, but the tDCS device will only be active for a few minutes at the beginning and end of the session.

HIIT alone: This involves just the cycling exercise with no brain stimulation. Who Can Participate?

The researchers are looking for women who:

Are 18-65 years old and have been diagnosed with fibromyalgia Experience moderate to high levels of pain Have stable blood pressure (if they have hypertension) Are not regularly active (don't do more than 30 minutes of exercise at least 3 times per week)

What Will the Study involve?

The participant will:

Attend 6 conditioning sessions (cycling) over two weeks to prepare their body. Complete 4 weeks of HIIT training, three times per week, at Universidad Andres Bello.

Attend 3 assessment sessions in our lab: before the conditioning, before the training, and after the training. These will include:

Non-invasive tests to measure your physical fitness, muscle strength, and pain sensitivity Brain and muscle connection tests. Questionnaires about your sleep, pain, fatigue, anxiety, depression, and exercise enjoyment

What the participant will get?

At the end of the study in addition to the training benefits, participants will receive a detailed report showing their body composition (muscle and fat levels) before and after the training.

Being tested
EXERCISE TRAINING WITH OR WITHOUT MEDICATION, Neuromodulators
Keywords
Fibromyalgia, central sensitization, Pain, intracortical excitability, HIIT - HIGH-INTENSITY INTERVAL TRAINING, tDCS - transcranial direct stimulation, transcranial magnetic stimulation
Medical subject headings
Fibromyalgia, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • EXERCISE TRAINING WITH OR WITHOUT MEDICATIONOther

    HIIT training: The participants will perform a HIIT protocol that consists of 1 minute of cycling at 50-60 revolutions per minute with a load that generates an effort of 80%-95% of their maximum Heart Rate (HR). Then 2 minutes of passive recovery, all this repeated 10 times (1x2x10). The effort of the session will be monitored by rating the perceived exertion (RPE) with a scale from 6-20 and HR. If the participant fails to recover within 2 minutes (>70% maximum heart rate), resting time will be extended until an HR ≤ 70% of the maximum is achieved. The maximum HR of each session will be used for HIIT prescription for the next session.

  • NeuromodulatorsOther

    Active tDCS: Two electrodes covered by a damp sponge will be placed on the scalp. The active electrode (anode) will be placed on the left motor cortex and the cathode on the contralateral supraorbital area before the exercise starts. The stimulation will start at the same time as the exercise, with an intensity of 2mA for 20 minutes.

Study groups in NCT07323199
Study groupRoleWhat they receive
HIGH-INTENSITY INTERVAL TRAINING (HIIT) plus active TRANSCRANIAL DIRECT CURRENT STIMULATION (tDCS)ExperimentalThe participants will cycle with a HIGH-INTENSITY INTERVAL TRAINING protocol while being stimulated with active TRANSCRANIAL DIRECT CURRENT STIMULATION for 20 minutes. This intervention will be performed three times per week for four weeks.
Receives: Other: EXERCISE TRAINING WITH OR WITHOUT MEDICATION; Other: Neuromodulators
HIGH-INTENSITY INTERVAL TRAINING (HIIT) plus sham TRANSCRANIAL DIRECT CURRENT STIMULATION (tDCS)Sham comparatorThe participants will cycle with a HIGH-INTENSITY INTERVAL TRAINING protocol while being stimulated with sham TRANSCRANIAL DIRECT CURRENT STIMULATION for 20 minutes. During exercise intervention, to replicate the feeling of current ramping up during active stimulation, the active anode placed on the left M1 will be activated for 30 seconds at the beginning and end of the procedure. This intervention will be performed three times per week for four weeks.
Receives: Other: EXERCISE TRAINING WITH OR WITHOUT MEDICATION; Other: Neuromodulators
HIGH-INTENSITY INTERVAL TRAINING (HIIT)Active comparatorThe participants will cycle with a HIGH-INTENSITY INTERVAL TRAINING protocol for 20 minutes without any stimulation. This intervention will be performed three times per week for four weeks.
Receives: Other: EXERCISE TRAINING WITH OR WITHOUT MEDICATION

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes of the numeric rating scale (0-10) for pain severity

    The primary outcome is the auto reported rating of pain severity with a numeric rating scale from 0 to 10 points. Commonly used to assess pain severity, where zero means "no pain" and 10 means "the worst pain imaginable". Participants will be asked to rate their pain sensation before and after the intervention.

    Measured: Participants will be asked to rate their pain sensation at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

Secondary outcomes (30)
  1. Changes in generalised perception of fatigue

    Generalised Fatigue: "is a profound and overwhelming, more severe, constant, and unpredictable than normal tiredness, not relieved by resting or sleep, not proportional to effort exerted, and disruptive in terms of motivation, activities, and cognition". The generalised fatigue will be assessed with:

    Multidimensional Fatigue Inventory (MFI). A questionnaire with 20 items divided into 5 domains: general fatigue, physical fatigue, mental fatigue, reduced activity and reduced motivation. The score range is between 4 to 20 points; a higher score indicates a greater degree of fatigue.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  2. Changes in generalised perception of fatigue

    The Symptom Severity (SS) Score, a tool that measures the severity of symptoms like fatigue, unrefreshed sleep, and cognitive issues, along with other somatic symptoms, over the past week. Rating the severity from 0 (no problem) to 3 (severe).

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  3. Changes in generalised perception of fatigue

    Fibromyalgia Impact Questionnaire (FIQR): The sub-item evaluates fatigue with a rating scale of 11 blocks (0 to 10). Higher scores indicate no energy.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  4. Changes in sleep quality

    The sleep quality will be measured with:

    Numeric Rating Scale (0-10): single-item tool that instructs the patient to describe the quality of sleep during the past 24 hours, where 0 is the best possible sleep and 10 is the worst possible sleep.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  5. Changes in sleep quality

    The sleep quality will be measured with:

    Pittsburgh Sleep Quality Index (PSQI): a questionnaire that assesses duration, disturbance, latency, daytime dysfunction due to sleepiness, sleep efficiency, overall sleep quality and sleep medication use. Each component is scored from 0 to 3. Low scores indicate good sleep quality and high scores indicate poor sleep quality. (0-4: Good sleep quality; 5-10: Poor sleep quality; >10: Very poor sleep quality).

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  6. Changes in the level of depression

    Depression will be assessed with two the subitem for depression of the "Fibromyalgia Impact Questionnaire (FIQR)". This goes from 0 to 10 in an 11-point rating scale with higher scores representing severity.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  7. Changes in the level of depression

    Beck's Depression Inventory II (BDI-II): a 21-item self-reported measure that assesses the cognitive, affective, and neurovegetative symptoms of depression. The total score is 63 points. The range score is 0-13 "minimal", 14-19 "mild", 20-28 "moderate" and 29-63 "severe".

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  8. Changes in quality of life

    Quality of life will be assessed with the "Fibromyalgia Impact Questionnaire (FIQR)", which is a 21-item self-administered questionnaire. The questionnaire has 3 domains: function, overall impact and symptoms. The total score ranges from 0 to 100 points; higher scores indicate a severe impact.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  9. Changes in quality of life

    Quality of life will be assessed with the "Short Form-36 (SF-36)". This questionnaire surveys health status, assesses physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional and mental health. The highest score is 100, and the higher the score, the better the quality of life.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  10. Changes corticospinal excitability

    To estimate corticospinal excitability peak-to-peak amplitude of the Motor Evoked Potential (MEP) will be measured. MEP is the response of the muscle to the stimulation of the corticomotor pathway with a magnetic stimulator and is measured with electromyography in milliAmpere (mA).

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  11. Adherence to training

    The adherence to exercise will be measured by the "Exercise Attitude Questionnaire". The score is 1 point "strongly disagree", 2 points "somewhat disagree", 3 points "somewhat agree", 4 points "strongly agree". The total score is 72 points, and the cut-off point for adherence is >60 points

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  12. Physical Activity

    Physical Activity Readiness Questionnaire (PAR-Q): pre-participation screening tool for detection of possible health and cardiovascular problems. Include seven health-related questions to be answered yes or no. If the answer is "yes" to one question, the participant should talk to a physician before starting physical activity. If all questions are yes, the participant is fit to perform physical activity.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  13. Physical Activity

    International Physical Activity Questionnaire (IPAQ): estimates the level of physical activity in different activity domains such as occupational, transport, yard/garden, household, leisure, and sitting. 27 items give a detailed picture of activity in different domains (work, transport, domestic, leisure). Measures frequency (days/week) and duration (minutes/day) of physical activity in the last 7 days, across intensity levels. It expresses activity in Metabolic Equivalent of Task (MET)-minutes per week (MET-min/week) or the energy cost of physical activities, where 1 MET is the energy expended at rest ≈ 3.5 mL O₂/kg/min. Higher values indicate greater physical activity level.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  14. Maximal voluntary isometric contraction

    It is the maximal voluntary effort of isometric contraction. The strength of the quadriceps will be evaluated during 3 trials using an isokinetic dynamometer (Isoforce®).

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  15. Muscle endurance

    A knee extension at 20% maximal voluntary contraction will be performed until exhaustion. Participants' perception of effort will be measured using the 15-point rating of perceived exertion (RPE) scale every 20 seconds of the time to exhaustion task.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  16. Aerobic capacity

    The aerobic capacity will be measured during an incremental cycling test. During this test, will be determined the maximum oxygen consumption (VO2peak) and the production of maximum concentric power (POmax)

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  17. Pain Sensitivity

    Pressure will be applied at an increasing rate of 50 kPa per second with an algometer placed perpendicular over the skin until the sensation of pressure changes to pain also known as pain pressure threshold (PPT).

    Measured: Participants will be asked to rate their pain sensation at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  18. Muscle soreness

    To quantify the muscle soreness, the participants must mark with a straight vertical line on the horizontal line (from 0 to 100 millimetres), after performing a task of sitting and standing 3 times.

    Measured: Participants will be asked to rate their pain sensation at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  19. Changes in the number of painful areas in the body

    The participant will report the number of painful areas of the body (upper, lower, or axial regions) over the last week. The total score is 19, where 1 region pain equals 1 point, divided by the left upper region, right upper region, axial region, left lower region and right lower region.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  20. Changes in Active Motor Threshold

    It is the lowest stimulus intensity of a transcranial magnetic stimulator to generate a motor evoked potential with a peak-to-peak amplitude of 200 microvolts in at least five out of 10 consecutive trials when the muscle is activated at 20% of the maximal voluntary contraction.

    Measured: Participants will be assessed before (T0) and after (T1) the four-week intervention.

  21. Changes in Resting Motor Threshold

    It is the lowest stimulus intensity of a transcranial magnetic stimulator to generate a motor evoked potential with a peak-to-peak amplitude of 50 microvolts in at least five out of 10 consecutive trials when the muscle is at rest.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  22. Changes in the silence period after the motor evoked potential

    It is the temporary interruption of the electromyographic signal from a muscle following a motor evoked potential. It is considered a measure of the excitability mediated by gamma-aminobutyric acid receptors. It will be measured in milliseconds (ms) from the end of the motor evoked potential wave to the recovery of the signal to the basal averaged amplitude.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  23. Changes in anxiety levels

    Changes in anxiety will be assessed with the subitem that evaluates anxiety of the "Fibromyalgia Impact Questionnaire (FIQR)" with 11 blocks (0 to 10), where higher scores indicate a severe impact.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  24. Changes in anxiety levels

    State Trait Anxiety Inventory (STAI) will be used to assess anxiety levels. The total score is 80 points. The score is classified as 20-37 "no or low anxiety", 38-44 "moderate anxiety" and 45-80 "high anxiety".

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  25. Level of enjoyment of exercise

    The enjoyment of exercise will be assessed with the "Physical Activity Enjoyment Scale". This scale includes 16 items with a maximum score of 80 points. The rating scale ranges from 1 ("dislike a lot") to 5 ("enjoy a lot").

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  26. Level of muscle soreness

    The participants will be asked to sit and stand 3 times with their legs shoulder-width apart and bend their knees to 90°. The volunteer must rate the level of discomfort by marking a straight vertical line on the horizontal line of a 100 mm rating scale. Higher values indicate greater soreness.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  27. Level of fear of movement

    The fear of movement will be assessed with the Tampa Scale for Kinesiophobia. A questionnaire of 17 questions, with a maximum of 68 points. Scores > 37 points indicate high levels of kinesiophobia, and ˂ 37 points indicate low levels.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  28. Changes in negative cognitions related to pain

    The catastrophization of pain will be assessed with a self-reported questionnaire designed to assess catastrophic thinking related to pain among adults. This "Pain Catastrophizing Scale" has 13 items, each describing a thought or feeling about pain. Each item is rated on a 5-point Likert scale from 0 to 4, with a maximal score of 52. Higher scores indicate high catastrophising.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  29. Changes in negative cognitions related to pain

    The acceptance of chronic Pain will be assessed with a 20-item questionnaire, "Chronic Pain Acceptance Questionnaire for Fibromyalgia", scored with a 7-point Likert scale (0 = "never true" to 6 = "always true"). Higher scores indicate better adjustment and functioning.

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

  30. Changes in body composition

    The weight and body composition in percentage of muscle, fat and water will be measured with a bioimpedanciometer (InBody 770).

    Measured: Participants will be assessed at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Jan 2026
  2. Study start1 Jan 2026 (estimated)
  3. Primary completionSep 2026 (estimated)
  4. Study completionJun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07323199
Sponsor's protocol ID
33B2024
Status last verified
Dec 2025
First submitted
30 Sep 2025
Last updated
7 Jan 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: There is no plan to make individual participant data (IPD) available to other researchers. The main reasons are related to the protection of participant confidentiality and the absence of formal mechanisms or resources to support secure data sharing. A summary of the results of the study will be published in peer-reviewed journals and presented at scientific meetings, ensuring transparency and dissemination of findings without compromising participant privacy.

Publications

  • Kolak E, Ardic F, Findikoglu G. Effects of different types of exercises on pain, quality of life, depression, and body composition in women with fibromyalgia: A three-arm, parallel-group, randomized trial. Arch Rheumatol. 2022 May 7;37(3):444-455. doi: 10.46497/ArchRheumatol.2022.9190. eCollection 2022 Sep.

    PubMed 36589612
  • Angius L, Pageaux B, Hopker J, Marcora SM, Mauger AR. Transcranial direct current stimulation improves isometric time to exhaustion of the knee extensors. Neuroscience. 2016 Dec 17;339:363-375. doi: 10.1016/j.neuroscience.2016.10.028. Epub 2016 Oct 14.

    PubMed 27751960
  • Martinez-Valdes E, Falla D, Negro F, Mayer F, Farina D. Differential Motor Unit Changes after Endurance or High-Intensity Interval Training. Med Sci Sports Exerc. 2017 Jun;49(6):1126-1136. doi: 10.1249/MSS.0000000000001209.

    PubMed 28121801
  • Hooten WM, Smith JM, Eldrige JS, Olsen DA, Mauck WD, Moeschler SM. Pain severity is associated with muscle strength and peak oxygen uptake in adults with fibromyalgia. J Pain Res. 2014 May 3;7:237-42. doi: 10.2147/JPR.S61312. eCollection 2014.

    PubMed 24833914
  • Kosek E, Ekholm J, Nordemar R. A comparison of pressure pain thresholds in different tissues and body regions. Long-term reliability of pressure algometry in healthy volunteers. Scand J Rehabil Med. 1993 Sep;25(3):117-24.

    PubMed 8248762
  • Ziemann U, Lonnecker S, Steinhoff BJ, Paulus W. Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol. 1996 Sep;40(3):367-78. doi: 10.1002/ana.410400306.

    PubMed 8797526
  • Kujirai T, Caramia MD, Rothwell JC, Day BL, Thompson PD, Ferbert A, Wroe S, Asselman P, Marsden CD. Corticocortical inhibition in human motor cortex. J Physiol. 1993 Nov;471:501-19. doi: 10.1113/jphysiol.1993.sp019912.

    PubMed 8120818
  • Groppa S, Oliviero A, Eisen A, Quartarone A, Cohen LG, Mall V, Kaelin-Lang A, Mima T, Rossi S, Thickbroom GW, Rossini PM, Ziemann U, Valls-Sole J, Siebner HR. A practical guide to diagnostic transcranial magnetic stimulation: report of an IFCN committee. Clin Neurophysiol. 2012 May;123(5):858-82. doi: 10.1016/j.clinph.2012.01.010. Epub 2012 Feb 19.

    PubMed 22349304
  • Pacheco-Barrios K, Lima D, Pimenta D, Slawka E, Navarro-Flores A, Parente J, Rebello-Sanchez I, Cardenas-Rojas A, Gonzalez-Mego P, Castelo-Branco L, Fregni F. Motor cortex inhibition as a fibromyalgia biomarker: a meta-analysis of transcranial magnetic stimulation studies. Brain Netw Modul. 2022 Apr-Jun;1(2):88-101. doi: 10.4103/2773-2398.348254. Epub 2022 Jun 29.

    PubMed 35845034
  • Hupfeld KE, Swanson CW, Fling BW, Seidler RD. TMS-induced silent periods: A review of methods and call for consistency. J Neurosci Methods. 2020 Dec 1;346:108950. doi: 10.1016/j.jneumeth.2020.108950. Epub 2020 Sep 22.

    PubMed 32971133
  • Zeugin D, Ionta S. Anatomo-Functional Origins of the Cortical Silent Period: Spotlight on the Basal Ganglia. Brain Sci. 2021 May 27;11(6):705. doi: 10.3390/brainsci11060705.

    PubMed 34071742
  • Hoeger Bement MK, Weyer AD, Yoon T, Hunter SK. Corticomotor excitability during a noxious stimulus before and after exercise in women with fibromyalgia. J Clin Neurophysiol. 2014 Feb;31(1):94-8. doi: 10.1097/WNP.0000000000000025.

    PubMed 24492452
  • Ridding MC, Taylor JL. Mechanisms of motor-evoked potential facilitation following prolonged dual peripheral and central stimulation in humans. J Physiol. 2001 Dec 1;537(Pt 2):623-31. doi: 10.1111/j.1469-7793.2001.00623.x.

    PubMed 11731592
  • McManus WF, Walker EE, Musselman MM. Effect of hydrocortisone on the localization of endotoxin in the peripheral vascular system as determined by fluorescent antibody technique. Surg Forum. 1965;16:7-9. No abstract available.

    PubMed 5319693
  • Arturi P, Schneeberger EE, Sommerfleck F, Buschiazzo E, Ledesma C, Maldonado Cocco JA, Citera G. Adherence to treatment in patients with ankylosing spondylitis. Clin Rheumatol. 2013 Jul;32(7):1007-15. doi: 10.1007/s10067-013-2221-7. Epub 2013 Mar 21.

    PubMed 23515597

Questions about this trial

What is this clinical trial studying?

A study testing EXERCISE TRAINING WITH OR WITHOUT MEDICATION and Neuromodulators in people with Fibromyalgia (FM), run by Universidad Nacional Andres Bello at 1 site in Chile.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 7 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Chile. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Edith Elgueta Cancino, PhD (+56 22 6618606, edith.elgueta@unab.cl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes of the numeric rating scale (0-10) for pain severity (time frame: Participants will be asked to rate their pain sensation at baseline, pre-intervention(T0) and immediately after the four-week intervention (T1).). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07323199, which also lists 46 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in